1. Shanthi Mendis PP, Bo Norrving. World Health Organization, World Heart Federation, World Stroke Organization. Global atlas on cardiovascular disease prevention and control: policies, strategies, and interventions.2011. 164 p.
2. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. [European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)]. Giornale italiano di cardiologia. 2013 May;14(5):328-92. Linee guida europee sulla prevenzione delle malattie cardiovascolari nella pratica clinica (versione 2012). Quinta Task Force congiunta della Societa Europea di cardiologia e di altre societa sulla prevenzione delle malattie cardiovascolari nella pratica clinica (costituita da rappresentanti di nove societa e da esperti invitati).
3. Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Sr., Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Nov 12.
4. Zeller T, Blankenberg S. Blood-based gene expression tests: promises and limitations. Circ Cardiovasc Genet. 2013;6(2):139–40.
5. Crick FH. On protein synthesis. Symp Soc Exp Biol. 1958;12:138–63.